Literature DB >> 1551080

Cytogenetic analysis in children with acute nonlymphocytic leukemia.

I Petković1, J Konja, M Nakić.   

Abstract

In this work we present the results of cytogenetic analysis of the malignant cells in 27 children with acute nonlymphocytic leukemia (ANLL). The aim of our investigations was to determine the frequency and types of chromosome aberrations in our population of children with ANLL. Successful cytogenetic analysis was carried out in 24 (89%) patients. Aberrant karyotypes of malignant cells were established in 58% of the cases. The most frequent chromosomal abnormality was t(8;21), identified in 5 (20.8%) patients, i.e., 4 of 10 M2-ANLL. Aberration frequency of chromosome 11 was 16.6% and was identified in 3 of 8 M5-ANLL. Trisomy 8 and monosomy 7 were identified in one patient each with M3 and M2-ANLL, respectively. del(13), a rare chromosome aberration in hemoblastoses, was found in a child with M1,t(8;21) and the loss of chromosome Y. Translocation t(1;11;21) with a break in regions 1q23, 11q23, and 21q22, is unusual and was identified in a boy with M2-ANLL; it can be considered as a variant form of the t(8;21).

Entities:  

Mesh:

Year:  1992        PMID: 1551080     DOI: 10.1016/0165-4608(92)90103-f

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Trisomy 6 as the sole stemline abnormality in a patient with acute monocytic leukemia: a case report.

Authors:  Masahiro Manabe; Reiko Asada; Yuji Hagiwara; Dai Momose; Yasuyoshi Sugano; Takeshi Mazaki; Ki-Ryang Koh
Journal:  Am J Blood Res       Date:  2018-04-05

Review 2.  Global characteristics of childhood acute promyelocytic leukemia.

Authors:  L Zhang; A Samad; M S Pombo-de-Oliveira; G Scelo; M T Smith; J Feusner; J L Wiemels; C Metayer
Journal:  Blood Rev       Date:  2014-09-30       Impact factor: 8.250

3.  A chromosome study on 97 cases of acute nonlymphocytic leukemia M2.

Authors:  F J Chen; A D Yang; H B Fei
Journal:  J Tongji Med Univ       Date:  1994
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.